Eterna Therapeutics regains compliance with NASDAQ, ensuring continued listing for stock.

From GlobeNewswire: 2024-11-14 08:30:00

Eterna Therapeutics Inc. (Nasdaq: ERNA) has regained compliance with Nasdaq for continued listing, ensuring its stock will continue to trade on The Nasdaq Stock Market. The Company met the market value of listed securities standard of at least $35 million and all applicable continued listing standards. Eterna’s President and CEO, Sanjeev Luther, highlighted the company’s transformation into a debt-free, low burn rate, preclinical stage cell therapy company focused on advancing ERNA-101 for triple-negative breast cancer and platinum-resistant, TP53-mutant ovarian cancer. Eterna Therapeutics aims to bring new treatment options to cancer patients in need.



Read more at GlobeNewswire: Eterna Therapeutics Regains Compliance with NASDAQ for